Significantly, CD20+ B-cells and PD-L1 were found to be of prognostic significance in inflammatory breast cancer treated with neoadjuvant chemotherapy [36], with high CD20 also associated with a pathological complete response (pCR) in neoadjuvant chemotherapy, but not CD3 or CD8 [37]. Here, CD8A is linked to inflammatory breast carcinoma.